Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person14
AV Support 247 Limited
Company · 14094332
Support In Sport Group Limited
Company · 04235291
Engage Train Support Limited
Company · 15250469
Obelisk Legal Support Solutions Limited
Company · 07312074
WEST SUSSEX (WORTHING) LIMITED
Company · 13193222
SEP2 LIMITED
Company · 09988870
WM SUGDEN & SONS LIMITED
Company · 00540051
PCL TRANSPORT LIMITED
Company · 04353067
Portakabin Limited
Company · 00685303
Signis Limited
Company · 08983010
SLB LIMITED/NV
Company
WASHCO LIMITED
Company · 00231369
Momart Limited
Company · 01073437
WSP UK Limited
Company · 01383511
Primary record16
Atrium Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 2, 2026, Atrium Therapeutics, Inc. (the “Company”) issued a press release regarding its upcoming poster presentation on November 6, 2026 at the Hypertrophic Cardiomyopathy
Coherus Oncology, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 28, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release announcing the interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, i
Eikon Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 26, 2026, Eikon Therapeutics, Inc. (the “Company”) issued a press release announcing data from its TeLuRide-005 trial of EIK1001, which were presented at the 2026 European S
Climb Bio, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 24, 2026, Climb Bio, Inc. (the “Company”) issued a press release announcing initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary membran
Red Cat Holdings, Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On October 21, 2026, Red Cat Holdings, Inc., a corporation incorporated under the laws of the State of Nevada (“Red Cat”), entered into a Business Combination Agreem
Climb Bio, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 23, 2026, Climb Bio, Inc. (the “Company”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), issued a press release announcing results for additional Phase 1 data in healt
Evolution Metals & Technologies Corp. filed 8-K
Item 7.01 Regulation FD Disclosure On October 5, 2026, Evolution Metals & Technologies Corp. (the Company or EM&T ) issued a press release announcing that the Company will hold a ribbon-cutting ceremony on Thursday, Dece
Monte Rosa Therapeutics, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure On October 1, 2026, Monte Rosa Therapeutics, Inc. (the Company ) issued a press release titled Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study
ACADIA PHARMACEUTICALS INC filed 8-K
Item 7.01 Regulation FD Disclosure. On September 24, 2026, Acadia Pharmaceuticals Inc. (the Company ) announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program eval
FILANA THERAPEUTICS, INC. filed 8-K
Item 7.01. Regulation FD Disclosure. On September 22, 2026, Filana Therapeutics, Inc. (the Company ) issued a press release related to the matters described in Item 8.01 of this Current Report on Form 8-K. A copy of the
Cue Biopharma, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On September 20, 2026, Cue Biopharma, Inc. (the Company ) issued a press release announcing positive topline results from a Phase 2 clinical trial of CUE-221 in Chronic Spontaneous Ur
Corbus Pharmaceuticals Holdings, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 14, 2026, Corbus Pharmaceuticals Holdings, Inc. (the Company ) issued a press release announcing positive topline data from its CANYON-1 Phase 1b clinical trial of CRB-913
Elevance Health, Inc. filed 8-K
Item 7.01 - Regulation FD Disclosure Officers of Elevance Health, Inc. (the Company ) expect to speak with investors and analysts over the next several weeks. During these meetings, Company officers will reaffirm the Com
MetaVia Inc. filed 8-K
Item 7.01. Regulation FD Disclosures. On September 9, 2026, MetaVia Inc. (the “Company” ) issued a press release announcing results from a preclinical tissue distribution study (the “ DA-1726 Study ”) demonstrating that
Spyre Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. SPY003 SKYLINE Part A Induction Topline Results On September 8, 2026, Spyre Therapeutics, Inc. (“Spyre” or the “Company”) issued a press release announcing positive 12-week induction t
Structure Therapeutics Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 8, 2026, Structure Therapeutics Inc. (the Company) issued a press release announcing positive topline clinical trial results across its oral small molecule amylin and GLP-